About VAHO
Founded in 1990, the Virginia Association of Hematologists and Oncologists (VAHO) is the largest oncology professional organization in the state. VAHO comprises a powerful community of oncologists, nurse practitioners, physician assistants, pharmacists, and other multidisciplinary care providers involved in the treatment of patients with cancer.
Events Calendar view all
2026 Spring MeetingThu |
Industry News view all
12/27/2024FDA Approves BeiGene’s TEVIMBRA® (tislelizumab-jsgr) First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with ChemotherapyNew indication based on results from a global Phase 3 trial demonstrating TEVIMBRA plus chemotherapy significantly improved overall survival for patients with advanced gastric cancers Second FDA approval for TEVIMBRA in 2024 |
12/27/2024FDA Approves Bristol Myers Squibb’s Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo® (nivolumab) IndicationsOpdivo Qvantig is the first and only subcutaneously administered PD-1 inhibitor Given over three- to five-minutes, Opdivo Qvantig demonstrated consistent efficacy and showed a comparable safety profile to intravenous Opdivo in the Phase 3 CheckMate-67T trial |
12/20/2024FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal CancerBRAFTOVI in combination with cetuximab and mFOLFOX6 is the first and only combination regimen with targeted therapy approved for use as early as first-line for patients with metastatic colorectal cancer with a BRAF V600E mutation Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the Phase 3 BREAKWATER trial |
